Entyvio’s SC Form Accepted by US FDA for Review: Takeda

Takeda Pharmaceutical said on May 10 that the US FDA has accepted a biologics license application for a subcutaneous (SC) formulation of its inflammatory bowel disease treatment Entyvio (vedolizumab) for maintenance therapy in moderately to severely active ulcerative colitis (UC)...read more